Internet Archive Scholar

Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease

Jean-Christophe Simard, Jean-François Thibodeau, Martin Leduc, Mikael Tremblay, Alexandre Laverdure, François Sarra-Bournet, William Gagnon, Jugurtha Ouboudinar, Liette Gervais, Alexandra Felton, Sylvie Letourneau, Lilianne Geerts (+16 others)
2020 Scientific Reports  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (11.6 MB)
https://web.archive.org/web/20201108073039/https://www.nature.com/articles/s41598-020-69675-8.pdf?error=cookies_not_supported&code=7e2fe43d-6d3e-40a1-bc06-dc562c99e5e4

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL. The file type is application/pdf.

Non-alcoholic Fatty Liver Disease (NAFLD) is the most common form of liver disease and is associated with metabolic dysregulation. Although G protein-coupled receptor 84 (GPR84) has been associated with inflammation, its role in metabolic regulation remains elusive. The aim of our study was to evaluate the potential of PBI-4547 for the treatment of NAFLD and to validate the role of its main target receptor, GPR84. We report that PBI-4547 is a fatty acid mimetic, acting concomitantly as a GPR84
more » ... ntagonist and GPR40/GPR120 agonist. In a mouse model of diet-induced obesity, PBI-4547 treatment improved metabolic dysregulation, reduced hepatic steatosis, ballooning and NAFLD score. PBI-4547 stimulated fatty acid oxidation and induced gene expression of mitochondrial uncoupling proteins in the liver. Liver metabolomics revealed that PBI-4547 improved metabolic dysregulation induced by a high-fat diet regimen. In Gpr84-/- mice, PBI-4547 treatment failed to improve various key NAFLD-associated parameters, as was observed in wildtype littermates. Taken together, these results highlight a detrimental role for the GPR84 receptor in the context of meta-inflammation and suggest that GPR84 antagonism via PBI-4547 may reflect a novel treatment approach for NAFLD and its related complications.
doi:10.1038/s41598-020-69675-8 pmid:32728158 fatcat:g37u3khpxjbbno6aqasxgp6wqu
DOAJ
Citation

Jean-Christophe Simard, Jean-François Thibodeau, Martin Leduc, Mikael Tremblay, Alexandre Laverdure, François Sarra-Bournet, William Gagnon, Jugurtha Ouboudinar, Liette Gervais, Alexandra Felton, Sylvie Letourneau, Lilianne Geerts, Marie-Pier Cloutier, Kathy Hince, Ramon Corpuz, Alexandra Blais, Vanessa Marques Quintela, Jean-Simon Duceppe, Shaun D. Abbott, Amélie Blais, Boulos Zacharie, Pierre Laurin, Steven R. Laplante, Christopher R. J. Kennedy, Richard L. Hébert, François A. Leblond, Brigitte Grouix, Lyne Gagnon. "Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease." Scientific Reports 10.1 (2020) 12778